Literature DB >> 16228228

Expression of gastrin and its receptor in human gastric cancer tissues.

Keun Hur1, Mi Kyung Kwak, Hyuk-Joon Lee, Do Joong Park, Hyeon Kook Lee, Hye Seung Lee, Woo Ho Kim, Dov Michaeli, Han-Kwang Yang.   

Abstract

PURPOSE: Gastrin is a growth factor of cancerous and normal cells of the gastrointestinal tract, and its effect is known to be mediated by gastrin/cholecystokinin B (CCKB) receptor. This study was performed to investigate the prognostic significance and the expression profiles of gastrin and gastrin receptor in human gastric carcinoma tissues.
METHODS: We analyzed the expressions of gastrin and gastrin receptor by immunohistochemical staining using anti-gastrin Ab (Sigma, St. Louis, MO, USA) and anti-gastrin receptor Ab (Aphton Corp., Woodland, CA, USA) in 279 gastric adenocarcinoma patients. Patients' clinicopathologic features and prognoses were analyzed.
RESULTS: The gastrin expression rate in these patients was 47.7% (133/279) and the gastrin receptor expression rate was 56.5% (158/279). Gastrin expression was significantly higher in men than in women (54.3% vs. 34.1%), and higher in differentiated gastric adenocarcinoma than in the undifferentiated type (55.1% vs. 43.0%). The gastrin receptor expression rate was also significantly higher in men than in women (61.2% vs. 47.3%), and was higher in the differentiated type than in the undifferentiated type (72.9% vs. 46.5%), and significantly higher in the intestinal type than in the diffuse type (75.2% vs. 42.9%). Gastrin and gastrin/CCKB receptor expressions were not found to be significant prognostic factors in themselves. When focused on correlation between the co-expression of gastrin and gastrin/CCKB receptor and the survival, the prognosis of patients positive for both gastrin and gastrin receptor was significantly poorer than for those negative for gastrin and gastrin receptor in diffuse-type gastric cancer patients. However, multivariate analysis showed that only TNM stage was an independent prognostic factor of survival in diffuse-type gastric cancer patients.
CONCLUSIONS: This study shows that the expression rates of gastrin and gastrin receptor are high (about a half) in gastric carcinoma tissues, and that there is an association between gastrin and gastrin receptor expression. We also found that patients with diffuse-type gastric carcinoma tissues expressing both gastrin and gastrin receptor have a poorer prognosis than those negative for both, which suggests that gastrin acts as an autocrine growth factor in a subgroup of gastric carcinomas.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16228228     DOI: 10.1007/s00432-005-0043-y

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  35 in total

1.  Binding of gastrin(17) to human gastric carcinoma cell lines.

Authors:  J Weinstock; G S Baldwin
Journal:  Cancer Res       Date:  1988-02-15       Impact factor: 12.701

2.  Gastrin-releasing peptide receptor-mediated autocrine growth in squamous cell carcinoma of the head and neck.

Authors:  Miriam N Lango; Kevin F Dyer; Vivian Wai Yan Lui; William E Gooding; Christopher Gubish; Jill M Siegfried; Jennifer Rubin Grandis
Journal:  J Natl Cancer Inst       Date:  2002-03-06       Impact factor: 13.506

3.  Gastric hyperplasia in mice lacking the putative Cdc42 effector IQGAP1.

Authors:  S Li; Q Wang; A Chakladar; R T Bronson; A Bernards
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

4.  Plasma gastrin and gastric enterochromaffinlike cell activation and proliferation. Studies with omeprazole and ranitidine in intact and antrectomized rats.

Authors:  H Larsson; E Carlsson; H Mattsson; L Lundell; F Sundler; G Sundell; B Wallmark; T Watanabe; R Håkanson
Journal:  Gastroenterology       Date:  1986-02       Impact factor: 22.682

Review 5.  The peripheral cholecystokinin receptors.

Authors:  S Silvente-Poirot; M Dufresne; N Vaysse; D Fourmy
Journal:  Eur J Biochem       Date:  1993-08-01

Review 6.  Gastrin, CCK, signaling, and cancer.

Authors:  E Rozengurt; J H Walsh
Journal:  Annu Rev Physiol       Date:  2001       Impact factor: 19.318

7.  Gastrin deficiency results in altered gastric differentiation and decreased colonic proliferation in mice.

Authors:  T J Koh; J R Goldenring; S Ito; H Mashimo; A S Kopin; A Varro; G J Dockray; T C Wang
Journal:  Gastroenterology       Date:  1997-09       Impact factor: 22.682

8.  Effects of curative gastrinoma resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome.

Authors:  J R Pisegna; J A Norton; G G Slimak; D C Metz; P N Maton; J D Gardner; R T Jensen
Journal:  Gastroenterology       Date:  1992-03       Impact factor: 22.682

9.  Coexpression of gastrin and gastrin receptors (CCK-B and delta CCK-B) in gastrointestinal tumour cell lines.

Authors:  D F McWilliams; S A Watson; D M Crosbee; D Michaeli; R Seth
Journal:  Gut       Date:  1998-06       Impact factor: 23.059

10.  Gastrin and colorectal cancer: a prospective study.

Authors:  C M Thorburn; G D Friedman; C J Dickinson; J H Vogelman; N Orentreich; J Parsonnet
Journal:  Gastroenterology       Date:  1998-08       Impact factor: 22.682

View more
  20 in total

1.  Can Proximal Gastrectomy with Double-Tract Reconstruction Replace Total Gastrectomy? A Propensity Score Matching Analysis.

Authors:  Hyo Jung Ko; Ki Hyun Kim; Si-Hak Lee; Cheol Woong Choi; Su Jin Kim; Chang In Choi; Dae-Hwan Kim; Dong-Heon Kim; Sun-Hwi Hwang
Journal:  J Gastrointest Surg       Date:  2019-04-01       Impact factor: 3.452

Review 2.  Cholecystokinin and pancreatic cancer: the chicken or the egg?

Authors:  Jill P Smith; Travis E Solomon
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-10-31       Impact factor: 4.052

3.  [99mTc]Tc-DGA1, a Promising CCK2R-Antagonist-Based Tracer for Tumor Diagnosis with Single-Photon Emission Computed Tomography.

Authors:  Aikaterini Kaloudi; Panagiotis Kanellopoulos; Thorsten Radolf; Oleg G Chepurny; Maritina Rouchota; George Loudos; Fritz Andreae; George G Holz; Berthold Artur Nock; Theodosia Maina
Journal:  Mol Pharm       Date:  2020-07-07       Impact factor: 4.939

4.  Blocking gastrin and CCK-B autocrine loop affects cell proliferation and apoptosis in vitro.

Authors:  Jian Jiang Zhou; Man Ling Chen; Qun Zhou Zhang; Yan Zao; Yuan Xie
Journal:  Mol Cell Biochem       Date:  2010-06-18       Impact factor: 3.396

5.  Human gastrin mRNA expression up-regulated by Helicobacter pylori CagA through MEK/ERK and JAK2-signaling pathways in gastric cancer cells.

Authors:  Jianjiang Zhou; Yuan Xie; Yan Zhao; Shu Wang; Yu Li
Journal:  Gastric Cancer       Date:  2011-04-22       Impact factor: 7.370

Review 6.  Importance of gastrin in the pathogenesis and treatment of gastric tumors.

Authors:  Michael D Burkitt; Andrea Varro; D Mark Pritchard
Journal:  World J Gastroenterol       Date:  2009-01-07       Impact factor: 5.742

7.  A combinatorial approach for the design of complementarity-determining region-derived peptidomimetics with in vitro anti-tumoral activity.

Authors:  Peter Timmerman; Rodrigo Barderas; Johan Desmet; Danièle Altschuh; Susana Shochat; Martine J Hollestelle; Jo W M Höppener; Alberto Monasterio; J Ignacio Casal; Rob H Meloen
Journal:  J Biol Chem       Date:  2009-10-06       Impact factor: 5.157

Review 8.  Hypergastrinemia.

Authors:  Sunil Dacha; Mohammed Razvi; Julia Massaad; Qiang Cai; Mohammad Wehbi
Journal:  Gastroenterol Rep (Oxf)       Date:  2015-02-18

9.  A gastrin transcript expressed in gastrointestinal cancer cells contains an internal ribosome entry site.

Authors:  A M Grabowska; C A Berry; J Hughes; M Bushell; A E Willis; S A Watson
Journal:  Br J Cancer       Date:  2008-04-08       Impact factor: 7.640

10.  Influence of d-glutamine and d-glutamic acid sequences in optical peptide probes targeted against the cholecystokinin-2/gastrin-receptor on binding affinity, specificity and pharmacokinetic properties.

Authors:  Susanne Kossatz; Rosalba Mansi; Martin Béhé; Peter Czerney; Ingrid Hilger
Journal:  EJNMMI Res       Date:  2013-11-15       Impact factor: 3.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.